Mode
Text Size
Log in / Sign up

HIV

153 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for HIV

664 trials tracked for HIV: 169 in phase 3 or 4 and 69 with published results. The most-cited published study has 2819 citations.

664Trials tracked
169Phase 3 & 4
0Recruiting
69With published results
Phase distribution
Phase 4 92 Phase 3 77 Phase 2 97 Phase 1 46 Other / NA 352
  1. Phase 4 Strategic Timing of Antiretroviral Treatment Completed · 2,819 cited
  2. Phase 3 Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions Completed · 497 cited
  3. Phase 3 Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection Completed · 471 cited
  4. Phase 3 Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants Completed · 304 cited
  5. Phase 3 Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV Completed · 227 cited
  6. Phase 3 Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults Completed · 154 cited
Show 44 more trials
  1. Phase 3 ODYSSEY (PENTA 20) Completed · 124 cited
  2. Phase 4 Doxycycline PEP for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV PrEP Completed · 119 cited
  3. Phase 3 Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study Completed · 115 cited
  4. Phase 4 A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac) Completed · 111 cited
  5. Phase 4 HIV Persistence and Viral Reservoirs Completed · 99 cited
  6. Phase 3 To Assess Continued Safety of and Adherence to the Dapivirine (25 mg) Vaginal Ring-004 in Healthy, HIV-negative Women Completed · 99 cited
  7. Phase 3 Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure Completed · 86 cited
  8. Phase 4 Evaluation of Pre-exposure Prophylaxis Cascade in Pregnant and Breastfeeding Women in Cape Town (Formative Study) Completed · 79 cited
  9. Phase 4 Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals Completed · 70 cited
  10. Phase 4 Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone Therapy Completed · 50 cited
  11. Phase 4 Genetics and HIV-1 Protease Inhibitors Completed · 49 cited
  12. Phase 4 DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP Adherence Completed · 49 cited
  13. Phase 4 SEARCH CAB LA Dynamic Choice HIV Prevention Study Extension Completed · 46 cited
  14. Phase 3 B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B Completed · 44 cited
  15. Phase 4 Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds Completed · 43 cited
  16. Phase 3 A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care Completed · 43 cited
  17. Phase 3 Treatment Options for Protease Inhibitor-exposed Children Completed · 43 cited
  18. Phase 4 Effects of Raltegravir Based Regimen on Platelet Reactivity, Platelet-monocyte Aggregation and Immune Activation Completed · 36 cited
  19. Phase 4 Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use Completed · 35 cited
  20. Phase 3 Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292) Completed · 35 cited
  21. Phase 3 Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018) Completed · 34 cited
  22. Phase 3 Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018) Completed · 34 cited
  23. Phase 3 Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021) Completed · 34 cited
  24. Phase 3 Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017) Completed · 32 cited
  25. Phase 4 Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics Completed · 31 cited
  26. Phase 4 Impact of Everolimus on HIV Persistence Post Kidney or Liver Transplant Completed · 31 cited
  27. Phase 4 IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women Completed · 30 cited
  28. Phase 3 A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women Completed · 30 cited
  29. Phase 4 HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women Completed · 26 cited
  30. Phase 3 HIV Vaccine Trial in Thai Adults Completed · 23 cited
  31. Phase 4 Buprenorphine to Improve HIV Care Engagement and Outcomes Completed · 22 cited
  32. Phase 4 ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence Completed · 19 cited
  33. Phase 4 Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide Completed · 16 cited
  34. Phase 4 A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain Completed · 16 cited
  35. Phase 3 Therapy to Elevate CD4 Counts in HIV-1 Disease Completed · 16 cited
  36. Phase 4 Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine Completed · 14 cited
  37. Phase 3 Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Family Planning Services Completed · 14 cited
  38. Phase 3 Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up Completed · 13 cited
  39. Phase 4 Pre-exposure Prophylaxis (PrEP) Adherence Enhancement Guided by iTAB and Drug Levels for Women Completed · 12 cited
  40. Phase 4 The Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age Completed · 12 cited
  41. Phase 4 Uptake and Adherence to Daily Oral PrEP as a Primary Prevention Strategy for Young African Women: A Vanguard Study Completed · 12 cited
  42. Phase 4 Alcohol Drinkers' Exposure to Preventive Therapy for TB (ADEPTT) Completed · 11 cited
  43. Phase 4 Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection Completed · 11 cited
  44. Phase 4 Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir Completed · 11 cited

Showing the 50 most-cited and recently-updated of 664 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

HIV: what the trials found

New evidence indicates that the administration of Doravirine 100mg Tab resulted in a M:P Ratio of 0.26 (p=0.0085) 2.

In patients receiving DTG/3TC, the CD4:CD8 ratio was measured at 1.127 at week 24 and 1.210 at week 48, with a change from baseline of 1.167 and -0.027 respectively 4.

Treatment with PRO 140 (350 mg) showed that the proportion of participants achieving viral suppression (HIV-1 RNA < 50 Copies/mL) after experiencing virologic failure was 0.92 or 0.79 5. The time to achieving viral suppression following virologic failure was 78.6 or 60.89 5. Additionally, the proportion of participants with viral suppression at week 48 from the start of the PRO 140 treatment phase was 0.33, 0.54, and 0.41 5.

The offering of on-demand oral PrEP has been evaluated in a Phase 4 study 1. Additionally, an algorithm treatment was evaluated regarding smoking cessation behaviors 3.

Recent results — preliminary, needs further review

  • Dolutegravir (DTG) 0.5 mg/kg liquid suspension showed no drug-related safety failures through 2 weeks after discontinuation in infants 6.
  • A study on Truvada alone was conducted 7.
  • High-Intensity Interval Training (HIIT) did not show a statistically significant change in physical function (p=0.35) 8.
  • The Gender Affirming Abriendo Puertas (GAP) program showed no statistically significant differences in viral suppression at 6 months (p=0.489) or 1 year (p=0.465), nor in retention in care (p=0.763) 9.
  • Choice architecture significantly influenced the initiation of TPT; approximately 70-78% of patients newly starting ART initiated TPT within 90 days, compared to only 2-5% among established ART patients 13.

For the clinician treating this condition

  • Doravirine 100mg Tab demonstrated a significant M:P Ratio of 0.26 2.
  • PRO 140 (350 mg) showed high rates of viral suppression following virologic failure, with varying success rates at week 48 5.
  • Choice architecture is an effective tool for increasing TPT initiation among patients newly starting ART 13.

AI synthesis of 10 cited trials, updated Aug 2, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Questions about HIV

Why does HIV/AIDS continue to have a disproportionate impact on Black people in the US?

HIV/AIDS disproportionately affects Black people in the US due to systemic inequities including healthcare access barriers, stigma, criminalization, and underrepresentation in research and community engagement.

Full answer →
How can machine learning predict my CD4 and CD8 counts if I have HIV/AIDS?

Machine learning models can predict your CD4 and CD8 counts by analyzing patterns in your routine blood tests, organ function, and other clinical data over time, helping doctors personalize your HIV care.

Full answer →
Can bictegravir and lenacapavir suppress HIV-1 just as well as my complex current regimen?

Yes, a once-daily bictegravir-lenacapavir single-tablet regimen is non-inferior to complex regimens for maintaining HIV-1 suppression at 48 weeks, based on phase 3 trial data.

Full answer →
Did the number of new HIV infections among gay men change recently?

No, the number of new HIV infections among gay men in the US did not change overall from 2010 to 2019.

Full answer →
Can an agricultural program help food insecure women with HIV in Kenya?

Yes, an agricultural program called Shamba Maisha reduced food insecurity and improved psychosocial outcomes for food insecure women with HIV in Kenya, including those who became pregnant.

Full answer →
What is the viral non-suppression rate for people with HIV in Uganda on dolutegravir?

In Uganda, about 6.4% of people with HIV on dolutegravir have viral non-suppression (viral load ≥1,000 copies/mL), based on a large routine-care cohort.

Full answer →
See all 6 questions about HIV →